131 related articles for article (PubMed ID: 7643626)
21. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
[TBL] [Abstract][Full Text] [Related]
22. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells.
Drexler HG; Quentmeier H
Leukemia; 1996 Sep; 10(9):1405-21. PubMed ID: 8751457
[TBL] [Abstract][Full Text] [Related]
23. The flt3/flk-2 ligand: receptor distribution and action on murine haemopoietic cell survival and proliferation.
Rasko JE; Metcalf D; Rossner MT; Begley CG; Nicola NA
Leukemia; 1995 Dec; 9(12):2058-66. PubMed ID: 8609717
[TBL] [Abstract][Full Text] [Related]
24. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.
Zheng R; Klang K; Gorin NC; Small D
Leuk Res; 2004 Feb; 28(2):121-6. PubMed ID: 14654075
[TBL] [Abstract][Full Text] [Related]
25. Fms-related tyrosine kinase 3 expression discriminates hematopoietic stem cells subpopulations with differing engraftment-potential: identifying the most potent combination.
Huang Y; Ratajczak MZ; Reca R; Xu H; Tanner M; Rezzoug F; Hussain LR; Fugier-Vivier I; Bolli R; Ildstad ST
Transplantation; 2008 Apr; 85(8):1175-84. PubMed ID: 18431239
[TBL] [Abstract][Full Text] [Related]
26. Fms-like tyrosine kinase 3 catalytic domain can transduce a proliferative signal in FDC-P1 cells that is qualitatively similar to the signal delivered by c-Fms.
Rossner MT; McArthur GA; Allen JD; Metcalf D
Cell Growth Differ; 1994 May; 5(5):549-55. PubMed ID: 8049161
[TBL] [Abstract][Full Text] [Related]
27. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells.
Williams NS; Klem J; Puzanov IJ; Sivakumar PV; Bennett M; Kumar V
J Immunol; 1999 Sep; 163(5):2648-56. PubMed ID: 10453005
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the mitogenic pathway of the FLT3 receptor and characterization in its C terminal region of a specific binding site for the PI3' kinase.
Casteran N; Rottapel R; Beslu N; Lecocq E; Birnbaum D; Dubreuil P
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):443-56. PubMed ID: 7920189
[TBL] [Abstract][Full Text] [Related]
29. Paracrine and autocrine growth mechanisms of human stem cell factor (c-kit ligand) in myeloid leukemia.
Pietsch T
Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):285-6. PubMed ID: 7687773
[TBL] [Abstract][Full Text] [Related]
30. Murine flt3 ligand protects M1 leukemic cells from LIF-induced differentiation and suppression of self-renewal.
Begley CG; Rasko JE; Curtis D; Takagi K; Metcalf D; Hilton D; Roberts B; Nicola NA; Rossner MT
Exp Hematol; 1996 Aug; 24(10):1247-57. PubMed ID: 8765501
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+).
Weimar IS; Miranda N; Muller EJ; Hekman A; Kerst JM; de Gast GC; Gerritsen WR
Exp Hematol; 1998 Aug; 26(9):885-94. PubMed ID: 9694510
[TBL] [Abstract][Full Text] [Related]
32. Flt3/Flk-2 and c-Kit are not essential for the proliferation of B lymphoid progenitor cells in the bone marrow of the adult mouse.
Ogawa M; Sugawara S; Kunisada T; Sudo T; Hayashi S; Nishikawa S; Kodama H; Nishikawa S
Exp Hematol; 1998 Jun; 26(6):478-88. PubMed ID: 9620281
[TBL] [Abstract][Full Text] [Related]
33. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
Zheng R; Levis M; Piloto O; Brown P; Baldwin BR; Gorin NC; Beran M; Zhu Z; Ludwig D; Hicklin D; Witte L; Li Y; Small D
Blood; 2004 Jan; 103(1):267-74. PubMed ID: 12969963
[TBL] [Abstract][Full Text] [Related]
34. Expression of the monocyte-specific esterase gene in leukemia-lymphoma cell lines.
Uphoff CC; Gignac SM; Metge K; Zschunke F; Radzun HJ; Drexler HG
Leukemia; 1993 Jan; 7(1):58-62. PubMed ID: 8418380
[TBL] [Abstract][Full Text] [Related]
35. Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells.
Weisel KC; Yildirim S; Schweikle E; Kanz L; Möhle R
Ann Hematol; 2009 Mar; 88(3):203-11. PubMed ID: 18797870
[TBL] [Abstract][Full Text] [Related]
36. The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta.
Veiby OP; Jacobsen FW; Cui L; Lyman SD; Jacobsen SE
J Immunol; 1996 Oct; 157(7):2953-60. PubMed ID: 8816402
[TBL] [Abstract][Full Text] [Related]
37. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors.
Inoue M; Kyo S; Fujita M; Enomoto T; Kondoh G
Cancer Res; 1994 Jun; 54(11):3049-53. PubMed ID: 7514496
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand.
McClanahan T; Culpepper J; Campbell D; Wagner J; Franz-Bacon K; Mattson J; Tsai S; Luh J; Guimaraes MJ; Mattei MG; Rosnet O; Birnbaum D; Hannum CH
Blood; 1996 Nov; 88(9):3371-82. PubMed ID: 8896402
[TBL] [Abstract][Full Text] [Related]
39. Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.
Williams B; Atkins A; Zhang H; Lu D; Jimenez X; Li H; Wang MN; Ludwig D; Balderes P; Witte L; Li Y; Zhu Z
Leukemia; 2005 Aug; 19(8):1432-8. PubMed ID: 15931264
[TBL] [Abstract][Full Text] [Related]
40. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias.
Carow CE; Levenstein M; Kaufmann SH; Chen J; Amin S; Rockwell P; Witte L; Borowitz MJ; Civin CI; Small D
Blood; 1996 Feb; 87(3):1089-96. PubMed ID: 8562934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
